Skip to main content
. 2021 Jun 27;17:60. doi: 10.1186/s13223-021-00550-5

Fig. 2.

Fig. 2

Patient opinions and experience with C1INH(SC) replacement therapy. Concepts and themes that emerged from 5 or more patient interviews out of N = 14 total interviews. HAE hereditary angioedema, C1INH(SC) subcutaneous C1 inhibitor